Comparative Pharmacology
Head-to-head clinical analysis: LANREOTIDE ACETATE versus SIGNIFOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANREOTIDE ACETATE versus SIGNIFOR.
LANREOTIDE ACETATE vs SIGNIFOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lanreotide is a synthetic octapeptide analog of somatostatin. It binds predominantly to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. It also reduces secretion of gastrointestinal hormones such as serotonin and gastrin.
Somatostatin analog; inhibits growth hormone (GH), insulin-like growth factor 1 (IGF-1), and other hormones.
90 mg subcutaneously every 4 weeks
Subcutaneous injection: 0.3 mg twice daily; Intravenous bolus: 0.9 mg (for Cushing's disease perioperatively).
None Documented
None Documented
Terminal elimination half-life: 23-30 hours following subcutaneous administration; prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life is approximately 5-6 hours in healthy subjects. In patients with renal impairment, half-life may be prolonged (up to 10 hours in severe impairment).
Primarily renal (approximately 60-70% of dose excreted unchanged in urine), with biliary/fecal elimination accounting for about 30%.
Primarily renal (approximately 80% of the dose excreted unchanged in urine), with about 20% eliminated via biliary/fecal routes. Renal clearance accounts for ~70% of total clearance.
Category C
Category C
Somatostatin Analog
Somatostatin Analog